SuppreMol is pioneering the development of soluble Fc gamma receptors (sFcγRs), which are recombinant autologous therapeutic proteins with a specific immunoregulatory potential. The most advanced clinical product, SM101, is a soluble Fc gamma receptor IIB (sFcγRIIB), which competes with FcγRs expressed on immune cells for pathogenic immune complexes.
Interference at this early stage of the immune reaction prevents the triggering of the cascade that results in inflammation and tissue destruction. In addition to immune complex competition, SM101 interferes with the formation of memory/plasma cells that are causative for the formation of new pathogenic antibodies. This dual mode of action indicates SM101’s potential as a therapy for different autoimmune diseases.
Furthermore, the Company is developing several antibody candidates that either target specific subtypes of Fc receptors or IL-3 for the treatment of further autoimmune diseases and allergies. See: SM201; SM301; SM401.
SuppreMol GmbH was founded in 2002 as a spin-off from the Max Planck Institute (MPI) of Biochemistry in Martinsried/Munich. The founders - Dr. Uwe Jacob, Dr. Peter Sondermann, and Prof. Dr. Robert Huber, Nobel Prize for Chemistry in 1988 - are internationally recognized experts in the field of protein crystallography. Using this technique they were able to identify the interaction of immunoglobulin G (IgG) antibodies with their cellular receptors termed Fcγ Receptors (FcγRs) at the atomic level. In 2005, SuppreMol was brought to corporate life with an initial seed investment.